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We highlight the risk of missing a high-grade
(Gleason Grade 7/8) transition zone adenocarci-
noma in a patient presenting with perineal dis-
comfort on sitting.
Introduction
Prostate cancer is the most frequent malignancy of
men of all races
1 and is the biggest cause of cancer
deaths in men
2 but there is continuing controversy
surrounding screening for prostate cancer
3 even
though the seriousness of prostate cancer is
unquestioned
4 with 0.6% of cases diagnosed as
early as 35–44 years of age.
5
The limitations of PSA use and, more speciﬁ-
cally, false positives and false negatives are
well known and some investigators have tried to
improve the method’s sensitivity and speciﬁcity,
including PSA adjusted by age, as well as PSA
density, velocity and fractions,
6 i.e. free/total
PSA ratio (%fPSA).
Despite imperfections which limit their
interpretation, the recently published large ran-
domized screening trials show there is only a
small – or no – improvement in survival from
early detection over the ﬁrst 10 years.
7 However,
in the recent European Randomized Study of
Screening for Prostate Cancer (ERSPC) by Schro ¨-
der et al.,
8 most centres involved in the trial used
a PSA cut-off value of 3 ng/mL (range of 3.0–
10.0 ng/mL depending on the country involved)
as an indication for biopsy; in the large American
randomized study by Andriole et al.
9 the standard
US threshold of 4 ng/mL was used. Using their
PSA values, Schro ¨der et al.
8 concluded that PSA-
based screening reduced the rate of death from
prostate cancer by 20% in their 55–69 year age
group of men at entry to the trial. The Andriole
et al.
9 trial concluded that, after 7–10 years of
follow-up, the death rate was very low, not
differing signiﬁcantly between their two study
groups.
Signiﬁcant prostate cancer can exist with
PSA levels of 2.5–4 ng/mL.
10 Thompson et al.
11
looked at the prevalence of prostate cancer,
including high-grade cancer, with PSA levels of
4.0 ng/mL and found 15% had prostate cancer
despite ‘normal PSA levels’, i.e. levels generally
thought to be in the normal range (4.0 ng/mL
or less). A transrectal ultrasound (TRUS) guided
biopsy of the prostate gland is the only way
that prostate cancer can be diagnosed with
certainty.
12 However, TRUS alone has poor test
characteristics for the diagnosis of prostate cancer
withapositivepredictivevalueof52.7%,anegative
predictive value of 72%, and an accuracy of 67%.
13
Biopsy cancer tissue is graded microscopically
using the Gleason score
14 with a possible total
rating from 2–10. Fast-growing (i.e. ‘high-grade’
cancers with a Gleason score of 7–10 usually
need more radical treatment.
12
Prostate cancer frequently originates from the
peripheral zone and only approximately 24%
arise from the transition zone where they are difﬁ-
cult to diagnose.
15
Barry
16 refers to many available treatment
options including surgery, radiation, cryotherapy,
and expectant management, and Jang et al.
17
state it is essential for men to have access to
balanced information before choosing a particular
therapy. Hoffman et al.
18 highlight the importance
of an informed and shared decision-making
process between the patient and urologist for pros-
tate cancer screening, treatment decisions, and
their possible sequelae.
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CASE REPORT
1Anatomy
There are four basic anatomical regions (Figure 1):
(i) anterior ﬁbromuscular stroma;
19 (ii) peripheral
zone constituting over 70% of the glandular pros-
tate; (iii) central zone (25%); and (iv) small tran-
sition zone consisting of two lobes essentially
located anteriorly between the proximal urethra
and the lateral parts of the peripheral zone.
20
Case presentation
A healthy, active and employed 68-year-old man
on no medication, and with no family history of
prostate cancer in his long-living male relatives
except for his maternal grandfather, consulted
his general medical practitioner for minor discom-
fort/paraesthesia in the perineal region, while
seated, of approximately three weeks duration.
A current digital rectal examination (DRE) of the
prostate indicated a suspicious ridge on the
right and a current PSA test showed a level of
1.8 ng/mL, the overall rise being from only 1.2
to 1.8 ng/mL over a 15-year period. However, in
view of the perineal symptom, and the DRE
ﬁnding, he was referred for an urosurgical
opinion. Two questionnaires, respectively, were
completed as diagnostic tools for any possible
erectile dysfunction (International Index of Erec-
tile Function
21) and prostate symptoms (Inter-
national Prostate Symptom Score
22); the scores
showed no dysfunction. In view of the patient’s
unexplained minor perineal discomfort/para-
esthesia on sitting and the DRE ﬁnding, the urolo-
gist recommended a TRUS biopsy of the prostate
gland with 12 biopsy cores. The TRUS did not
show any abnormality but the biopsy indicated a
T2a adenocarcinoma with a Gleason score of 6 on
the left side. Treatment options were discussed
with the patient, consideration being given to one
of three approaches: ‘watchful waiting’, radiation
therapy, or a laparoscopic radical prostatectomy;
the patient chose the latterapproach as, in the urol-
ogist’s experience, the actual Gleason score could
be higher when the excised gland was sent for
pathological evaluation.
Results
The prostate and some associated tissues were
sent for pathological evaluation. In summary, the
pathology report concluded: prostate adenocarci-
noma representing a high-grade transition zone
carcinoma occupying the anterior aspect on the
left (Figure 2) consistent with Gleason Grade 4+
3= 7, Grade 4/5= 70% (pattern 5=10%), with
associated intraductal carcinoma. Tumour is pros-
tate and specimen conﬁned, with a volume of
2.13cc and a pathological stage of T2a. Sections
through the ejaculatory ducts, seminal vesicles
and bladder neck margin conﬁrm all structures
to be free of tumour.
Postoperatively at six weeks and three months,
respectively, the patient’s PSA level was found to
be 0.03 ng/mL.
Discussion
Worldwide, in 2002, more than 670,000 men were
diagnosed with prostate cancer; the highest rates
were in the USA and the lowest in Asian
countries.
23 It is estimated that 192,280 USA men
will be diagnosed with, and 27,360 men will die
from, prostate cancer in 2009.
5 In Australia, more
than 61,000 men are diagnosed with prostate
cancer and another 19,000 will be diagnosed in
Figure 1
Side view diagram of the prostate showing the
anterior ﬁbromuscular stroma (FM), central zone
(CZ), posterior zone (PZ), transition zone (TZ),
prostatic urethra (PU), and a seminal vesicle
(SV). Modiﬁed from Prostate UK (http://www.
prostateuk/prg/prostate/aboutprostate.htm)
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2the next year;
2in spite of theseﬁgures, population-
wide PSA screening is not recommended.
24
According to Hoffman,
3 aP S At h r e s h o l db e l o w
4.0 ng/mL should not be used to trigger biopsy
referral, however, Dall’oglio et al.
4 suggest that
prostate biopsy is indicated in men with a PSA
level of 2.5–4.0 ng/mL, highlighting the current
uncertainty regarding a meaningful PSA value.
The PSA level of only 1.8 ng/mL in the case pre-
sented above indicates that even a PSA level of
2.5 ng/mL can be too high. Perhaps the real indi-
cators of the prostate adenocarcinoma in this case
were the perineal symptoms while seated, as peri-
neal pain sometimes occurs with prostate cancer,
25
coupled with the overall increase in PSA from 1.2
to 1.8 ng/mL over the 15-year period.
Conclusions
Of relevance to general practitioners it should be
noted that, although Holmstro ¨m et al.
26 concluded
from their longitudinal study that PSA has a rela-
tively high validity for prediction of subsequent
prostate cancer, no cut-off value was established,
although PSA concentrations below 1.0 ng/mL
were considered to ‘virtually rule out a diagnosis
of prostate cancer during follow-up and high
PSA concentrations expressed a continuum of
prostate cancer risk’. In spite of this, Schro ¨der
et al.
8 used a cut-off value of 3.0–10.0 ng/mL
depending on the European country involved
and Andriole et al.
9 used a cut-off value of
4.0 ng/mL – had they used a l.0 ng/mL cut-off
they may well have reached different conclusions,
particularly as Hugosson et al.
27 recently found
that mortality was reduced almost by half over a
14-year period when using a PSA cut-off value
of 3.0 ng/mL. Perhaps a 1.0 ng/mL cut-off would
further reduce mortality until newer diagnostic
technology becomes available.
Based on the above, it is suggested the PSA risk
level for patients should be revised downwards
and that a large clinical study should be per-
formed using a much lower PSA level such as
1.0 ng/mL.
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